Table 2.
Laboratory measurements of the patients enrolled in the study.
| Laboratory measurements |
SM (n=37) | TMZ (n=39) | Control (n=40) | P-value | |
|---|---|---|---|---|---|
| ALT (U/l) | baseline | 28.24 ± 24.84 | 25.23 ± 14.45 | 25.20 ± 21.99 | 0.547 |
| 7 d | 29.00 ± 21.77 | 22.15 ± 11.15 | 22.88 ± 17.09 | 0.406 | |
| AST(U/l) | baseline | 31.35 ± 21.03 | 32.85 ± 15.59 | 32.28 ± 22.11 | 0.197 |
| 7 d | 32.65 ± 20.25 | 29.18 ± 11.86 | 28.80 ± 14.80 | 0.552 | |
| Creatinine (μmol/l) |
baseline | 110.40 ± 40.24 | 104.97 ± 40.73 | 112.20 ± 33.92 | 0.381 |
| 7 d | 104.58 ± 34.71 | 106.72 ± 44.51 | 112.04 ± 41.97 | 0.614 | |
| FFA (μmol/l) | baseline | 670.73 ± 228.75 | 645.39 ± 222.14 | 689.58 ± 235.65 | 0.692 |
| 7 d | 469.60 ± 231.33 | 526.77 ± 212.51 | 562.73 ± 207.60 | 0.172 | |
| Glucose (mmol/l) |
baseline | 5.40 ± 1.26 | 5.81 ± 2.31 | 5.38 ± 1.25 | 0.848 |
| 7 d | 5.13 ± 0.90 | 5.71 ± 1.80 | 5.43 ± 1.73 | 0.446 | |
| LA (mmol/l) | baseline | 2.48 ± 0.98 | 2.22 ± 0.75 | 2.13 ± 0.75 | 0.168 |
| 7 d | 1.95 ± 0.67 | 1.89 ± 0.62 | 1.75 ± 0.52 | 0.308 | |
| PA (μg/ml) | baseline | 17.09 ± 8.22 | 16.56 ± 6.23 | 16.61 ± 10.19 | 0.595 |
| 7 d | 14.55 ± 7.47 | 15.47 ± 6.39 | 15.84 ± 9.45 | 0.461 | |
| BCAA (nmol/μl) | baseline | 0.46 ± 0.17 | 0.44 ± 0.17 | 0.45 ± 0.21 | 0.925 |
| 7 d | 0.55 ± 0.16 | 0.46 ± 0.14 | 0.48 ± 0.17 | 0.053 | |
| BNP (log10)a | baseline | 2.87 ± 0.36 | 2.97 ± 0.38 | 2.92 ± 0.42 | 0.538 |
| 7 d | 2.32 ± 0.40 | 2.48 ± 0.47 | 2.57 ± 0.48 | 0.060 |
Values are expressed as the mean ± SD. ALT, Alanine Transaminase; AST, Aspartate Transaminase; FFA, Free Fatty Acids; LA, Lactic Acid; PA, Pyroracemic Acid; BCAA, Branched Chain Amino Acid; BNP, B-type Natriuretic Peptide. aBNP level was logarithm base 10-transformed before the analysis.